ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 605,58
0,45%
Dow Jones
38 778,10
0,49%
DAX
18 120,20
0,26%
Brent Oil
83,775
-0,15%
Bitcoin
65 299,31
-1,79%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Kronos Bio Inc (KRON)

  7. Kronos Bio Inc (KRON) Actualités

KRON

Kronos Bio (KRON)

Kronos Bio Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:KRON
DateHeureSourceTitreSymboleSociété
04/06/202423h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
04/06/202422h58Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
23/05/202423h15GlobeNewswire Inc.Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:KRONKronos Bio Inc
22/05/202422h30GlobeNewswire Inc.Kronos Bio to Participate in Three Upcoming Healthcare Conferences and EventsNASDAQ:KRONKronos Bio Inc
21/05/202422h15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KRONKronos Bio Inc
21/05/202414h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRONKronos Bio Inc
21/05/202414h15GlobeNewswire Inc.Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer NASDAQ:KRONKronos Bio Inc
09/05/202422h08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KRONKronos Bio Inc
09/05/202422h05GlobeNewswire Inc.Kronos Bio Reports First-Quarter 2024 Financial ResultsNASDAQ:KRONKronos Bio Inc
21/03/202412h05GlobeNewswire Inc.Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial ResultsNASDAQ:KRONKronos Bio Inc
07/03/202422h05GlobeNewswire Inc.Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash RunwayNASDAQ:KRONKronos Bio Inc
05/03/202422h44GlobeNewswire Inc.Kronos Bio To Present Three Posters at AACR 2024 Annual MeetingNASDAQ:KRONKronos Bio Inc
27/02/202422h05GlobeNewswire Inc.Kronos Bio Announces Participation in 44th Annual Cowen Health Care ConferenceNASDAQ:KRONKronos Bio Inc
18/12/202322h06GlobeNewswire Inc.Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development CandidateNASDAQ:KRONKronos Bio Inc
04/12/202314h00GlobeNewswire Inc.Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceNASDAQ:KRONKronos Bio Inc
27/11/202322h05GlobeNewswire Inc.Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:KRONKronos Bio Inc
13/11/202322h05GlobeNewswire Inc.Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial ResultsNASDAQ:KRONKronos Bio Inc
02/11/202321h05GlobeNewswire Inc.Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 StudyNASDAQ:KRONKronos Bio Inc
02/11/202317h00GlobeNewswire Inc.Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual MeetingNASDAQ:KRONKronos Bio Inc
27/10/202314h00GlobeNewswire Inc.Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual MeetingNASDAQ:KRONKronos Bio Inc
13/10/202318h30GlobeNewswire Inc.Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTCNASDAQ:KRONKronos Bio Inc
04/10/202322h05GlobeNewswire Inc.Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13NASDAQ:KRONKronos Bio Inc
17/08/202314h00GlobeNewswire Inc.Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate DevelopmentNASDAQ:KRONKronos Bio Inc
08/08/202322h05GlobeNewswire Inc.Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial ResultsNASDAQ:KRONKronos Bio Inc
26/06/202323h19Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KRONKronos Bio Inc
26/06/202322h16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KRONKronos Bio Inc
06/06/202314h00GlobeNewswire Inc.Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality AssuranceNASDAQ:KRONKronos Bio Inc
01/06/202322h05GlobeNewswire Inc.Kronos Bio Announces Participation in Upcoming Investor ConferencesNASDAQ:KRONKronos Bio Inc
30/05/202322h36Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:KRONKronos Bio Inc
10/05/202322h05GlobeNewswire Inc.Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial ResultsNASDAQ:KRONKronos Bio Inc
 Showing the most relevant articles for your search:NASDAQ:KRON

Dernières Valeurs Consultées

NASDAQI
OMRXTOT
OMRX Total Market
EU
FRSG00014EV9
SG Issuer Sg Issuer Mc F...
NYSE
GAS
Nicor
BMF
CNHN24
CNHN24 - Julho 2024
LSE
87JY
Cred Ag Co.30
NASDAQ
FHHTKX
Us Equity Closedend Port...
COIN
MQSTUST
MonsterQuest
LSE
BX29
Ivz 2029 Usd D
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés